Koers PharmaCyte Biotech, Inc. Other OTC
Aandelen
PMCB
US71715X1046
Farmaceutische producten
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 50,93 mln. 46,95 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -4 mln. -3,69 mln. | Nettowinst (verlies) 2023 | -4 mln. -3,69 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 85,4 mln. 78,71 mln. | Nettoliquiditeiten 2023 | 68,04 mln. 62,71 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-8,53
x | K/w-verhouding 2023 |
-13,2
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 35,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joshua Silverman
CEO | Chief Executive Officer | 53 | 15-08-22 |
Carlos Trujillo
DFI | Director of Finance/CFO | 66 | 01-01-15 |
José Iglesias
CTO | Chief Tech/Sci/R&D Officer | - | 10-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Weinstein
BRD | Director/Board Member | 64 | 14-11-22 |
Joshua Silverman
CEO | Chief Executive Officer | 53 | 15-08-22 |
Wayne Walker
BRD | Director/Board Member | 65 | 28-12-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,96% | 705 mld. | |
+32,57% | 583 mld. | |
-3,06% | 364 mld. | |
+21,34% | 332 mld. | |
+6,05% | 291 mld. | |
+16,21% | 238 mld. | |
-3,56% | 210 mld. | |
+10,52% | 209 mld. | |
+9,38% | 169 mld. |